The development of fixed dose combinations and drug repurposing projects are commonly adopted lifecycle management strategies for the enhancement of individual drugs. These strategies tend to reduce the side effects or assessment of clinical efficacy in newer indications. Combining drugs that may have been shelved due to a variety of reasons with established, safe and approved drugs has the potential to bring safer, effective therapies to patients. In addition to this, there are also IP and business advantages to combining drugs. A systematic, risk based scientific strategy and leveraging the available data is important to bring efficiencies in shortening the development timeline.
Listen to this webinar to hear from industry expert, Anil Kane, Ph.D, about: